FDA approves Toviaz for overactive bladder

Pfizer has received FDA approval for Toviaz (fesoterodine fumarate extended-release tablets) for the treatment of overactive bladder (OAB). In two randomized, placebo-controlled studies involving >1600 patients, Toviaz-treated patients had significantly fewer incontinence episodes and a decreased number of times needed to urinate per day as compared to placebo.

Toviaz will be available in 4mg and 8mg dosage strengths.

For more information call (800) 438-1985 or visit www.toviaz.com.